Clinical Trial: Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT04140123) titled 'Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)' on Oct. 15.

Brief Summary: Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic steatohepatitis (NASH).

Study Type: Interventional

Condition: Non-Alcoholic Steatohepatitis (NASH)

Intervention: * Drug: ZSP1601

ZSP1601 tablets be taken orally for 28 days.

* Drug: ZSP1601 Placebo

Subjects will receive matching placebo of ZSP1601

Recruitment Status: Not Yet Recruiting

Sponsor: Guangdong Raynovent Biotech Co., Ltd...